Caliper Life Sciences Inc. of Hopkinton, Mass., has signed a multiyear license agreement with Novartis International AG of Basel, Switzerland, in which the latter company will have access to its partner’s noninvasive in vivo optical imaging methods. Among the technologies covered under the agreement are instruments from Caliper’s Xenogen product line, including a system that allows both bioluminescence and fluorescence imaging.